Korro Bio Reports FY Loss, Revenue Surges 181.9%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 12 2026
0mins
Should l Buy KRRO?
Source: seekingalpha
- Earnings Miss: Korro Bio reported a FY GAAP EPS of -$12.48, missing expectations by $3.43, indicating challenges in profitability that could dampen investor confidence.
- Revenue Surge: The company achieved revenue of $6.4M, a remarkable 181.9% year-over-year increase, exceeding market expectations by $1M, suggesting strong market acceptance of its products or services and laying a foundation for future growth.
- Successful Fundraising: Korro announced an oversubscribed $85 million private placement, reflecting investor confidence in its future prospects, with funds earmarked for accelerating R&D and market expansion.
- Market Engagement: Korro Bio presented at the J.P. Morgan Healthcare Conference, garnering attention from analysts and investors, which may lead to increased collaboration opportunities and market exposure.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KRRO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KRRO
Wall Street analysts forecast KRRO stock price to rise
8 Analyst Rating
0 Buy
8 Hold
0 Sell
Hold
Current: 10.280
Low
7.00
Averages
25.75
High
81.00
Current: 10.280
Low
7.00
Averages
25.75
High
81.00
About KRRO
Korro Bio, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Loar Holdings and Korro Bio Insider Trading Updates
- Charles Dirkson Purchase: On Thursday, Charles R. Dirkson bought 44,000 shares of LOAR at $67.45 each, totaling an investment of $2.97 million, indicating strong confidence in the company's future.
- Market Reaction: Despite Dirkson's purchase price of $67.45, LOAR shares are currently trading at $62.98, which is 6.6% below his purchase price, reflecting short-term market volatility.
- Korro Bio Insider Buying: Rick Yang purchased 207,100 shares of Korro Bio on Tuesday at $11.11 each, totaling an investment of $2.30 million, signaling optimism about the company's prospects.
- Stock Performance: Korro Bio is up 11.1% on Friday, with shares reaching a high of $14.79 during trading, resulting in a 33.1% return on Yang's investment at the peak of the trading session.
See More
Korro Bio Stock Rises on Earnings Beat and Analyst Upgrades
- Earnings Beat: Korro Bio's latest earnings report reveals significant revenue growth, driving stock price appreciation and reflecting strong performance and market confidence in the biopharmaceutical sector.
- Analyst Upgrades: Several analysts have upgraded their outlook on Korro Bio, citing the substantial market potential of its new drug candidate, which enhances investor expectations for the company's future growth.
- New Drug Candidate Highlight: The newly introduced drug candidate is considered to have breakthrough advancements in treating specific diseases, with potential positive outcomes in upcoming clinical trials, further boosting stock performance.
- Long-Term Growth Strategy: Korro Bio plans to increase R&D investments, focusing on the development of innovative drugs, aiming for sustainable long-term growth through continuous technological advancements and market expansion.
See More
KORRO BIO INC: RAYMOND JAMES UPGRADES TO OUTPERFORM FROM MARKET PERFORM
Raymond James Raises Outlook: The financial services firm Raymond James has increased its performance outlook based on recent market trends.
Market Performance Insights: The adjustments in outlook reflect a positive assessment of market conditions and potential growth opportunities.
See More
Korro Bio Reports FY Loss, Revenue Surges 181.9%
- Earnings Miss: Korro Bio reported a FY GAAP EPS of -$12.48, missing expectations by $3.43, indicating challenges in profitability that could dampen investor confidence.
- Revenue Surge: The company achieved revenue of $6.4M, a remarkable 181.9% year-over-year increase, exceeding market expectations by $1M, suggesting strong market acceptance of its products or services and laying a foundation for future growth.
- Successful Fundraising: Korro announced an oversubscribed $85 million private placement, reflecting investor confidence in its future prospects, with funds earmarked for accelerating R&D and market expansion.
- Market Engagement: Korro Bio presented at the J.P. Morgan Healthcare Conference, garnering attention from analysts and investors, which may lead to increased collaboration opportunities and market exposure.
See More
Korro Bio Secures $85 Million in PIPE Financing
- Financing Agreement: Korro Bio has entered into a subscription agreement for a private investment in public equity, securing approximately $85 million, which reflects strong market confidence in its future growth prospects.
- Stock Issuance Details: Under the agreement, Korro is selling 4.5 million shares of common stock at $11.11 per share and offering 3.15 million pre-funded warrants at an exercise price of $0.001, thereby enhancing its capital structure.
- Use of Funds: The net proceeds from this financing, combined with $85.2 million in cash and cash equivalents as of December 31, 2025, will extend the company's cash runway into the second half of 2028 and support the clinical development of its pipeline for genetic disease therapies.
- Advancing Clinical Milestones: The funding will facilitate clinical development milestones for key pipeline assets, including clinical data for KRRO-121 and the GalNAc-conjugated alpha-1 antitrypsin deficiency program, ensuring ongoing innovation in treatment areas.
See More
Korro Bio Secures $85 Million PIPE Financing to Advance RNA Editing Programs
- Financing Amount: Korro Bio has secured approximately $85 million through PIPE financing, which will support the reporting of clinical data for multiple RNA editing programs, particularly the KRRO-121 project for patients with urea cycle disorders, indicating the company's strong growth potential in gene therapy.
- Investor Participation: The financing was led by Venrock Healthcare Capital Partners and attracted participation from several new and existing investors, including ADAR1 Capital Management and New Enterprise Associates, reflecting market confidence and support for Korro's RNA editing technology.
- Cash Flow Extension: Following this financing, Korro expects to extend its cash runway into the second half of 2028, ensuring operational stability for several years alongside $85.2 million in cash and cash equivalents as of December 31, 2025.
- Clinical Development Milestones: The funds will drive clinical development for KRRO-121 and the GalNAc-conjugated oligonucleotide program targeting alpha-1 antitrypsin deficiency, further solidifying Korro's market position and technological advantages in the gene therapy sector.
See More
Loar Holdings and Korro Bio Insider Trading Updates
- Charles Dirkson Purchase: On Thursday, Charles R. Dirkson bought 44,000 shares of LOAR at $67.45 each, totaling an investment of $2.97 million, indicating strong confidence in the company's future.
- Market Reaction: Despite Dirkson's purchase price of $67.45, LOAR shares are currently trading at $62.98, which is 6.6% below his purchase price, reflecting short-term market volatility.
- Korro Bio Insider Buying: Rick Yang purchased 207,100 shares of Korro Bio on Tuesday at $11.11 each, totaling an investment of $2.30 million, signaling optimism about the company's prospects.
- Stock Performance: Korro Bio is up 11.1% on Friday, with shares reaching a high of $14.79 during trading, resulting in a 33.1% return on Yang's investment at the peak of the trading session.
See More
Korro Bio Stock Rises on Earnings Beat and Analyst Upgrades
- Earnings Beat: Korro Bio's latest earnings report reveals significant revenue growth, driving stock price appreciation and reflecting strong performance and market confidence in the biopharmaceutical sector.
- Analyst Upgrades: Several analysts have upgraded their outlook on Korro Bio, citing the substantial market potential of its new drug candidate, which enhances investor expectations for the company's future growth.
- New Drug Candidate Highlight: The newly introduced drug candidate is considered to have breakthrough advancements in treating specific diseases, with potential positive outcomes in upcoming clinical trials, further boosting stock performance.
- Long-Term Growth Strategy: Korro Bio plans to increase R&D investments, focusing on the development of innovative drugs, aiming for sustainable long-term growth through continuous technological advancements and market expansion.
See More
KORRO BIO INC: RAYMOND JAMES UPGRADES TO OUTPERFORM FROM MARKET PERFORM
Raymond James Raises Outlook: The financial services firm Raymond James has increased its performance outlook based on recent market trends.
Market Performance Insights: The adjustments in outlook reflect a positive assessment of market conditions and potential growth opportunities.
See More
Korro Bio Reports FY Loss, Revenue Surges 181.9%
- Earnings Miss: Korro Bio reported a FY GAAP EPS of -$12.48, missing expectations by $3.43, indicating challenges in profitability that could dampen investor confidence.
- Revenue Surge: The company achieved revenue of $6.4M, a remarkable 181.9% year-over-year increase, exceeding market expectations by $1M, suggesting strong market acceptance of its products or services and laying a foundation for future growth.
- Successful Fundraising: Korro announced an oversubscribed $85 million private placement, reflecting investor confidence in its future prospects, with funds earmarked for accelerating R&D and market expansion.
- Market Engagement: Korro Bio presented at the J.P. Morgan Healthcare Conference, garnering attention from analysts and investors, which may lead to increased collaboration opportunities and market exposure.
See More
Korro Bio Secures $85 Million in PIPE Financing
- Financing Agreement: Korro Bio has entered into a subscription agreement for a private investment in public equity, securing approximately $85 million, which reflects strong market confidence in its future growth prospects.
- Stock Issuance Details: Under the agreement, Korro is selling 4.5 million shares of common stock at $11.11 per share and offering 3.15 million pre-funded warrants at an exercise price of $0.001, thereby enhancing its capital structure.
- Use of Funds: The net proceeds from this financing, combined with $85.2 million in cash and cash equivalents as of December 31, 2025, will extend the company's cash runway into the second half of 2028 and support the clinical development of its pipeline for genetic disease therapies.
- Advancing Clinical Milestones: The funding will facilitate clinical development milestones for key pipeline assets, including clinical data for KRRO-121 and the GalNAc-conjugated alpha-1 antitrypsin deficiency program, ensuring ongoing innovation in treatment areas.
See More
Korro Bio Secures $85 Million PIPE Financing to Advance RNA Editing Programs
- Financing Amount: Korro Bio has secured approximately $85 million through PIPE financing, which will support the reporting of clinical data for multiple RNA editing programs, particularly the KRRO-121 project for patients with urea cycle disorders, indicating the company's strong growth potential in gene therapy.
- Investor Participation: The financing was led by Venrock Healthcare Capital Partners and attracted participation from several new and existing investors, including ADAR1 Capital Management and New Enterprise Associates, reflecting market confidence and support for Korro's RNA editing technology.
- Cash Flow Extension: Following this financing, Korro expects to extend its cash runway into the second half of 2028, ensuring operational stability for several years alongside $85.2 million in cash and cash equivalents as of December 31, 2025.
- Clinical Development Milestones: The funds will drive clinical development for KRRO-121 and the GalNAc-conjugated oligonucleotide program targeting alpha-1 antitrypsin deficiency, further solidifying Korro's market position and technological advantages in the gene therapy sector.
See More
